A STUDY OF CERVICAL LESIONS IN CORRELATION WITH HUMAN PAPILLOMAVIRUS ANALYSIS BY IMMUNOHISTOCHEMICAL ASSAY

Authors

  • P NEERAJA Department of Pathology, A. C. Subba Reddy Government Medical College, Nellore, Andhra Pradesh, India.
  • C BHAKTHAVATSALA REDDY Department of Cardiology, Narayana Medical College and Hospitals, Nellore, Andhra Pradesh, India.
  • C LAKSHMI KALAVATHI Department of Pathology, A. C. Subba Reddy Government Medical College, Nellore, Andhra Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i5.47895

Keywords:

Human papillomavirus, Histopathology, Oncogenesis, Immunohistochemical assay

Abstract

Objective: It has become clear that human papillomavirus (HPV) plays a critical role in the pathogenesis of nearly all cervical squamous cell carcinomas. Because HPV causes a variety of cervix lesions, including benign, premalignant, and malignant lesions, early detection of this infection benefits the patient.

 The goal of this study is to identify neoplastic and non-neoplastic cervix lesions, to study neoplastic and non-neoplastic cervix lesions caused by HPV in correlation with HPV analysis by immunohistochemistry (IHC), and to understand the significance of HPV in screening cervical lesions.

Methods: The current study evaluated and compared HPV cocktail expression in 100 samples collected from 100 cases with cervical lesions. A semi-quantitative method was used to determine the positivity of the HPV cocktail. Comparison of expression of HPV cocktail IHC and histopathology was carried out.

Results: Of the 100 cases, 30 were carcinoma cervix (CC), 4 were carcinoma in situ (CIS), 22 were squamous intraepithelial lesions (SIL), 20 were chronic cervicitis, 16 were chronic cervicitis with Koilocytic change, 7 were Koilocytic change, and 1 was Inflammatory polyp. SIL and CIS have a mean age of 46.8 and 44.5 years, respectively. There was a 42% incidence of carcinoma cases seen in the fourth decade, with a mean age of 45.9 years. The most common complaint presented by CC patients is AUB, with postmenopausal bleeding being the most common complaint. Seven patients with Squamous cell carcinoma present with postmenopausal bleeding. There were neoplastic lesions in 56% of the cases and non-neoplastic lesions in 44% of the cases. Premalignant cervix lesions include low grade squamous intra epithelial lesion, high grade squamous intra epithelial lesion, and CIS, which account for 46.42% of all cases. Non-neoplastic lesions such as chronic cervicitis account for 45.55% of all cases, followed by chronic cervicitis with Koilocytic change (36.36%), Koilocytic change (15.91%), and Polyp (2.27%). There were 28 Squamous cell carcinomas and 2 Adenocarcinomas among the 30 cases of CC. Squamous cell carcinoma accounted for 93.33% of all cases, while adenocarcinoma accounted for 6.67%. Moderately differentiated squamous cell carcinomas account for 86.66% of the cases, followed by well differentiated squamous cell carcinomas and poorly differentiated squamous cell carcinomas, which account for 6.66% of the cases. 26 (86.6%) of 30 squamous cell carcinomas tested positive for IHC. All two Adenocarcinoma cases (100%) and all CIS cases (100%) were positive. Out of the 22 SIL cases, 18 (81.81%) were positive. Out of 16 cases of chronic cervicitis with Koilocytic change, 14 (87.5%) were positive. Out of 20 chronic cervicitis cases, 12 (60%) were positive. 5 (71.43%) of the 7 cases of Koilocytic change were positive. Cervical lesions (benign, premalignant, and malignant) have a significant correlation with HPV cocktail IHC (p=0.01).

Conclusion: The expression of the HPV cocktail was associated with clinical and histopathologic parameters in benign, premalignant, and malignant cervical lesions. Periodic follow-up allows patients to be better managed by providing vital data on the incidence of HPV infection in various cervical lesions. Low-grade SILs and high-grade SILs with HPV +ve infection can be monitored by HPV once a year instead of every 6 months. Patients over the age of 30 years with HPV-positive non-neoplastic cervical lesions can be monitored once every three years rather than annually. HPV is a biomarker for a better prognosis in cervical cancer, regardless of age, International Federation of Obstetricians and Gynecologists stage, or histologic type. HPV-positive tumors have a better prognosis.

Downloads

Download data is not yet available.

References

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. doi: 10.3322/ caac.20107, PMID 21296855

Koss LG. The Papanicolaou test for cervical cancer detection: A triumph and a tragedy. JAMA 1989;261:737-43. doi: 10.1001/ jama.1989.03420050087046, PMID 2642983

McCluggage WG, Walsh MY, Thornton CM, Hamilton PW, Date A, Caughley LM, et al. Inter- and intra-observer variation in the histopathological reporting of cervical squamous intra-epithelial lesions using a modified Bethesda grading system. BJOG 1998;105:206-10. doi: 10.1111/j.1471-0528.1998.tb10054.x

Tornesello ML, Duraturo ML, Giorgi-Rossi P, Sansone M, Piccoli R, Buonaguro L, et al. Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. J Gen Virol 2008;89:1380-9. doi: 10.1099/vir.0.83553-0, PMID 18474553

Arbyn M, de Sanjose S, Weiderpass E. HPV-based cervical cancer screening, including self-sampling, versus screening with cytology in Argentina. Lancet Glob Health 2019;7:e688-9. doi: 10.1016/S2214- 109X(19)30067-1, PMID 31097266

Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials. Lancet 2014;383:524-32. doi: 10.1016/S0140-6736(13)62218-7, PMID 24192252

Fatima Q, Verma S, Bairwa NK, Gauri LA. Spectrum of various lesions in cervical biopsies in North West Rajasthan: A prospective histopathological study. Int J Res Prof 2017;3:104-11.

Ali MH, Ahmed HG, Salih RA. Histopathologic Pattern of Cervical Lesions at Omdurman Military Hospital, Sudan. Sch J App Med Sci 2015;3:2903-7.

Rosai J. Female reproductive system-uterus: Cervix. In: Rosai and Ackerman’s Surgical Pathology. 10th ed., Ch. 19. Netherlands, MO: Elsevier Ltd.; 2011. p. 1436-76.

Jain A, Dhar R, Patro P, Sahu S. Histopathological study of cervical lesions. Int J Health Sci Res. 2018;8:82-7.

Kumari K, Umarani MK, Bharathi M. Histopathological spectrum of cervical biopsies- a 5 year retrospective study. Trop J Pathol Microbiol 2017;3:46-51.

Bagde S, Gupta R, Ganguly S, Bhardwaj A, Jogi S. Spectrum of cervical lesions in CIMS, Bilaspur: A 5 year retrospective study of 215 cases in a Tertiary Hospital of Central India. J Evid Based Med Healthc 2015;2:7505-10. doi: 10.18410/jebmh/2015/1014

Singh N, Bannur H. A cross-sectional study of p53 expression in patients with squamous cell carcinoma cervix: A hospital-based study. Indian J Health Sci Biomed Res 2017;10:203-7.

Gupta M, Basavaraj PK. Histopathological spectrum of premalignant and malignant lesions of uterine cervix. Natl J Lab Med 2018;7:PO19-26.

Nwachokor FN, Forae GC. Morphological spectrum of non-neoplastic lesions of the uterine cervix in Warri, South-South, Nigeria. Niger J Clin Pract 2013;16:429-32.

Priyadarshini D, Arathi CA. Histopathological spectrum of non-neoplastic uterine Cervical lesions in a tertiary Care Center. Ann Pathol Lab Med 2017;4:A303-9.

Yadav V, Jaiswal M, Pandey S. A comparative study of p53 expression in premalignant and malignant cervical lesions at a tertiary care institute of Rohilkhand region, India. Int J Med Sci Public Health 2018;7:216-21.

Halle MK, Ojesina AI, Engerud H, Woie K, Tangen IL, Holst F, et al. Clinicopathologic and molecular markers in cervical carcinoma: A prospective cohort study. Am J Obstet Gynecol 2017;217:432.e1-17.

Baythoon SJ, Ali HH, Qasim B. Immunohistochemical expressionof P53 invasive cervical carcinoma (A Clinicopathological Study). Iraqi J Med Sci 2008;6:90-102.

Huang LW, Chou YY, Chao SL, Chen TJ, Lee TT. p53 and p21 Expression in precancerous lesions and carcinomas of the uterine cervix: Overexpression of p53 predicts poor disease outcome. Gynecol Oncol 2001;83:348-54. doi: 10.1006/gyno.2001.6397:53

Kakati J, Bhuyan B. A histopathological study of neoplastic lesions of uterine cervix of peri and postmenopausal women. J Evid Based Med Healthc 2017;4:1294-8.

Thakrar M, Mathur K. Immunohistochemical study of p53 expression as proliferative index in neoplasia of the uterine cervix. Int Arch Integr Med 2017;4:16-25.

Burd EM. Human papillomavirus laboratory testing: The changing paradigm. Clin Microbiol Rev 2016;29:291-319.

Siriaunkgul S, Suwiwat S, Settakorn J, Khunamornpong S, Tungsinmunkong K, Boonthum A, et al. HPV genotyping in cervical cancer in Northern Thailand: Adapting the linear array HPV assay for use on paraffin-embedded tissue. Gynecol Oncol 2008;108:555-60.

Rashed MM, Bekele A. The prevalence and pattern of HPV-16 immunostaining in uterine cervical carcinomas in Ethiopian women: A pilot study. Pan Afr Med J 2011;8:21. doi: 10.4314/pamj.v8i1.71077, PMID 22121430

Published

07-05-2023

How to Cite

NEERAJA, P., C. B. REDDY, and C. L. KALAVATHI. “A STUDY OF CERVICAL LESIONS IN CORRELATION WITH HUMAN PAPILLOMAVIRUS ANALYSIS BY IMMUNOHISTOCHEMICAL ASSAY”. Asian Journal of Pharmaceutical and Clinical Research, vol. 16, no. 5, May 2023, pp. 177-80, doi:10.22159/ajpcr.2023.v16i5.47895.

Issue

Section

Original Article(s)